Metropolis Healthcare Limited announced the launch of its Centre of Genomics on January 13, 2026, representing a major advancement in the company's precision diagnostics and genomic research capabilities. The initiative aims to scale the company's long-standing expertise in advanced genomics, molecular diagnostics, and precision medicine while broadening access to genomic insights across India's healthcare landscape.

Technology Infrastructure and Capabilities

The Centre of Genomics is built on a robust technological foundation featuring Illumina's NovaSeq™ X Series for research purposes. This cutting-edge sequencing platform incorporates Illumina's advanced XLEAP-SBS™ chemistry, delivering exceptional throughput, accuracy, and sustainability. The NovaSeq™ X Plus system demonstrates remarkable capacity, capable of generating more than 20,000 whole genomes annually—representing more than double the throughput of Illumina's previous sequencing systems.

Beyond the newly deployed NovaSeq™ X Series, the Centre operates with existing multi-platform NGS infrastructure across Metropolis' key genomics hubs. The facility brings together multidisciplinary teams including molecular pathologists, genomic scientists, researchers, bioinformaticians, and certified genetic counsellors to translate complex genomic data into clinically meaningful insights.

Laboratory Network and Accreditation

The Centre of Genomics operates through two CAP-accredited genomics laboratories strategically located in Delhi NCR and Mumbai. This integrated model combines the capabilities of Metropolis' Global Reference Laboratory in Mumbai with the specialized genomics laboratory acquired through the Core Diagnostics integration in the Delhi NCR region. The unified operation serves as national referral laboratories for genomics, providing comprehensive NGS-based assays, robust bioinformatics capabilities, and deep scientific expertise.

Clinical Focus Areas and Applications

The Centre of Genomics addresses multiple high-impact clinical specialties, delivering actionable genomic insights across the care continuum. The facility focuses on five key areas:

• Oncology: Precision cancer diagnostics and treatment guidance
• Reproductive Health: Genetic screening and fertility-related testing
• Neurology: Neurological disorder diagnosis and management
• Transplant Immunology: Compatibility testing and monitoring
• Rare Diseases: Diagnosis of genetic and inherited conditions

The Centre currently offers over 220 validated genomic tests with a clear expansion roadmap targeting more than 500 assays over the next two to three years. This growth strategy positions the facility among leading global genomic laboratories in terms of breadth, quality, and clinical integration while maintaining alignment with India-specific disease patterns and care pathways.

Leadership Perspectives and Strategic Vision

Ameera Shah, Promoter and Executive Chairperson of Metropolis Healthcare Limited, emphasized the transformative potential of genomics in Indian diagnostics. She highlighted how the Centre of Genomics combines orthogonal, cross-platform technologies with advanced data analytics and AI-driven trend correlations, supported by clinical stewardship from subject-matter experts and a multi-specialty Medical Advisory Board.

Dr. Kirti Chadha, Chief Scientific and Innovation Officer, outlined the Centre's focus on translating advanced genomic science into actionable clinical decision-making. The facility's differentiation lies in rigorous validation, multi-platform testing, and deep clinical integration to ensure reliable and clinically meaningful results.

Suchita Dayanand, Country Head – India (Commercial) at Illumina, expressed pride in supporting Metropolis Healthcare's research and innovation initiatives through the NovaSeq™ X Series deployment, emphasizing Illumina's mission to make advanced sequencing technologies more accessible across India.

Future Development and Global Positioning

The Centre of Genomics serves as a platform for continuous test development, AI-enabled analytics, and enhanced digital integration. These capabilities strengthen reporting quality, operational efficiency, and clinical impact while supporting Metropolis' B2B operations across multiple countries. The facility actively engages in pharmaceutical programs and clinical trials, positioning itself as a strategic partner for global research, companion diagnostics, and precision-led drug development initiatives.

Metropolis Healthcare shares gained over 4.60% to ₹2,021.40 on Monday following the company's positive third quarter business update. The diagnostic services provider delivered impressive consolidated revenue growth of 26% year-on-year for the quarter ended December 31, demonstrating robust operational performance across its healthcare portfolio.

Stock Performance and Market Reaction

The market responded positively to the company's strong quarterly performance, with shares trading significantly higher during morning sessions. The stock price appreciation reflects investor confidence in the company's growth trajectory and successful execution of its expansion strategy.

Consolidated Performance Highlights

The company's consolidated performance reflects strong execution across multiple business verticals and successful integration of recent acquisitions. The 26% consolidated revenue growth was driven by sustained momentum in preventive healthcare and specialty testing segments.

The consolidated growth includes contributions from Core Diagnostics, Scientific Pathology, Dr. Ahuja's Pathology & Imaging Center, and Dr. RS Patil's Ambika Pathology Laboratory. The integration of all acquisitions is progressing well, with synergies delivering operational efficiencies and strengthening operating leverage.

Standalone Business Performance

On a standalone basis, Metropolis Healthcare achieved solid growth metrics across key business segments, with overall revenue growth of approximately 15% year-on-year driven by increased patient and test volumes.

The growth was largely attributed to increased patient and test volumes, along with a favorable shift in product mix and realizations across the company's diversified revenue streams.

Operational Excellence and Margin Expansion

Despite the third quarter being a seasonally weaker period for the diagnostic industry, EBITDA margins expanded year-on-year, highlighting the resilience of operations and strength of the business model. The company has successfully scaled its specialty business across its pan-India network, supported by an expanded test menu for high-end specialty testing and continuous in-house innovation.

The B2B revenue growth of 37% was supported by increased wallet share among customers, especially in the specialty segment, and higher contribution from Core Diagnostics. Recent acquisitions including DAPIC, Scientific, and Ambika continue to outperform the company's average margins, indicating successful integration and operational synergies.